KO

KOMIPHARM INTERNATIONAL CO., LTD.

Develops animal health products and novel drugs for human cancer and autoimmune diseases.

041960 | KO

Overview

Corporate Details

ISIN(s):
KR7041960006
LEI:
Country:
South Korea
Address:
경기도 시흥시 경제로 17, 시흥시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Komipharm International Co., Ltd. is a biopharmaceutical company with core operations in animal health and a strategic focus on human therapeutics. The company develops, manufactures, and sells a diverse portfolio of veterinary products, including vaccines, pharmaceuticals, and disinfectants for livestock, poultry, and companion animals. Leveraging over 50 years of industry experience, Komipharm is also engaged in the research and development of novel drugs for human use. Its pharmaceutical pipeline concentrates on creating therapeutic agents for challenging indications such as cancer pain and autoimmune diseases, as part of its strategy to expand into the global bio-industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(약식)
Korean 122.0 KB
2025-09-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 78.6 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.9 MB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-07-30 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 61.3 KB
2025-07-07 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 10.8 KB
2025-06-20 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 37.4 KB
2025-06-20 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.7 KB
2025-05-27 00:00
Capital/Financing Update
주요사항보고서(제3자의전환사채매수선택권행사)
Korean 23.3 KB
2025-05-14 00:00
Annual Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-29 00:00
Share Issue/Capital Change
[기재정정]전환청구권행사
Korean 14.4 KB
2025-04-23 00:00
Share Issue/Capital Change
전환청구권행사
Korean 11.1 KB
2025-03-26 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 31.6 KB
2025-03-26 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 10.1 KB
2025-03-26 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 32.7 KB

Automate Your Workflow. Get a real-time feed of all KOMIPHARM INTERNATIONAL CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KOMIPHARM INTERNATIONAL CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KOMIPHARM INTERNATIONAL CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.